Tammuella Chrisentery-Singleton/LinkedIn
Aug 8, 2026, 20:37
Tammuella Chrisentery-Singleton: What Comes Next for Hemophilia Care With Non-Factor Therapies?
Tammuella Chrisentery-Singleton, Chief Science Officer at American Thrombosis and Hemostasis Network (ATHN), Co- Director Hemostasis and Thrombosis Program at Ochsner Health, shared a post on LinkedIn:
“After the long trip home from ISTH, I’m excited to bring new insights back to the clinic as we think about what comes next for
hemophilia care with non-factor therapies now being available across the world.
Note: This content is intended for healthcare professionals only.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!